The structure of the parent pyrido[1,2-a]pyrimidin-4-one ring system was settled by H. Antaki and V. Petrow in 1951, was characterized via ultraviolet spectroscopy from 1958–1962, and became the active core of globally marketed therapeutics.
The Question and the Era
This article reconstructs, from original documents, an obscure but highly consequential sequence in the history of a valuable chemical scaffold. The purpose is to preserve a precise account: what was corrected, how the correction was proved, how the work expanded into a general chemistry of condensed pyrimidines, and where that chemistry stands today.
The events belong to a period of structural chemistry now difficult to reconstruct without bias. Questions that are approached today by routinely combining NMR, mass spectrometry, crystallography, and computation had to be answered purely by chemical behavior, degradation, analogy, electronic reasoning, and independent synthesis. To evaluate the complexity of the problem fairly, one must look through the lens of the instruments and conceptual frameworks available to those who faced it at the time.
The achievement was finding the reasoning by which the structure could be understood within the constraints of the era. The question is how Antaki identified the decisive structural uncertainty and devised a way to resolve it under the conditions of 1950.
The Road (1950)
The compound at the center of the question had been prepared early in the century, and by 1950 its structure had been approached and re-approached for nearly four decades. In his doctoral thesis, Contributions to the Chemistry of Heterocyclic Compounds (University of London, 1950), H. Antaki set out that long history in full—giving each earlier worker their due.
A significant, overlooked aspect of this period was a deep-seated error in the existing literature regarding how pyridine derivatives condensed with aromatic acids. Early pioneers Reissert (1895) and Räth (1931) had confidently claimed that these reactions yielded 1,8-naphthyridine architectures (specifically, 2,3-benzo-4-hydroxy-1,8-naphthyridine). Räth had even attempted to validate this via an alkaline oxidation that yielded what he identified as "2-aminonicotinic acid," melting at 217°C—far below the true 310°C standard reported by Philips for the authentic compound.
Antaki's work confirmed that these products were actually 2,3-benzo-4-keto-1-aza-4-quinolizines. While oxidative degradation established the broader skeleton, it remained fundamentally blind to the finer question: the precise position of the carbonyl group within that skeleton.
As mapped in the original thesis records in IMG_5449_2.jpg, Antaki systematically charted the temperature-dependent pathways of 2-aminopyridine and ethyl acetoacetate to isolate the precise conditions under which intermediate compounds transitioned into the final base.
What the thesis added was an elegant explanation of why the ring formed as it did, leveraging structural electronic theory to clear up decades of confusion. The closure to one skeleton rather than its isomer, Antaki argued, received a ready explanation on the basis of chemical physics:
“The electronegativity of the nitrogen atom is known to be greater than that of carbon. An electron-releasing group at the appropriate position leads to an increase in the electron density on the nuclear nitrogen. Prototropic rearrangement follows,” directing the closure to the observed product.
Because the high electronegativity of the nuclear nitrogen in 2-aminopyridine increases electron density, it drives an electrophilic attack straight to the nuclear nitrogen rather than the carbon backbone. This was an argument from basic electronic principles—the reasoning of a chemist who understood the system from its core physics, not merely its raw products.
The Correction (1951)
The following year, the work was published alongside V. Petrow in the Journal of the Chemical Society. The paper directly addressed what degradation methods could not: earlier workers had assigned the product as the 2-oxo compound; Antaki and Petrow proved it was the 4-oxo isomer.
They supplied definitive proof via independent synthesis. By reacting 2-bromopyridine with ethyl β-aminocrotonate, they built the 4-oxo compound through a route that could uniquely yield that structure. The resulting product was identical to the long-disputed base (m.p. 122°C). The assignment was no longer an inference, but a result fixed by construction.
The same paper introduced the reagent that made the route general. Ethyl β-aminocrotonate was found to be “markedly superior” to older reagents (like ethyl acetoacetate) for this class of condensation, enabling a vast series of related compounds to become available for the first time. The correction of a single structure opened a gateway to a general methodology.
A General Chemistry: Systematic Structural Expansion
The correction of a single structure would have been a closed achievement. What followed made it the foundation of a field.
Antaki and Petrow deployed their optimized ethyl β-aminocrotonate methodology to carry the condensation far beyond 2-aminopyridine, systematically mapping previously inaccessible heterocyclic architectures where enolizably sluggish reagents had historically failed:
Fused Ring System Syntheses (Ph.D. Thesis, Part I)
| Target Ring System |
Thesis Page |
Reagents Used |
Key Findings and Structural Outcomes |
7,9-Diazathianaphten
(Section B) |
p. 33 |
2-Aminothiazole +
Ethyl β-aminocrotonate |
Bypassed previous synthetic failures in literature by Bogert & Masters; isolated the unknown 4-keto-6-methyl derivative. |
1,11-Diaza-9-thiafluorene
(Section C) |
p. 37 |
Substituted 2-aminobenzothiazoles +
Ethyl β-aminocrotonate |
Bypassed old German patent limitations that stopped at mono-acetoacetamides; successfully synthesized 6-chloro, 6-acetamido, 6-carbethoxy, and 6-ethoxy variants. |
1,11-Diaza-9-oxafluorene
(Section D) |
p. 39 |
2-Aminobenzoxazole +
Ethyl β-aminocrotonate |
Earliest reported synthesis of this specific ring system in chemical literature. |
1,11-Diazacarbazoles
(Section E) |
p. 41 |
2-Aminobenzimidazole +
Cycloalkanone-2-carboxylates |
Expanded the architecture to build 2,3-cyclotetramethylene and cyclotrimethylene variants. |
(Note: The experimental protocols and exact validation procedures for these systems begin collectively in Section F on Page 48 of the thesis).
Across two further papers—in the Journal of the American Chemical Society (1958) and the Journal of Organic Chemistry (1962)—Antaki determined their ultraviolet absorption spectra to decode the electronic identity of the class. He identified a core spectral band common to the whole family, attributable to the conjugated system of the pyrimidine ring. By 1962, the work formed a unified whole: a corrected parent structure, a general method for building on it, and a definitive spectroscopic account of the resulting family.
Independent Confirmations and the Cyanoacetate Series
The structural correction did not rest on the authors’ word; it was independently verified over the following two decades:
- Adams and Pachter (1952): Synthesized both the parent 2-one and 4-one independently, recorded their UV spectra as reference standards, and confirmed the Antaki-Petrow product was the 4-one.
- The Squibb Institute for Medical Research: Yale and colleagues repeated the reactions, finding their products identical in m.p., IR, UV, and PMR spectra, confirming the 4-one structures via X-ray crystallography.
- Separate Validation: The result was reached again by Shur and Israelstam (1968) as well as Kato and colleagues at Tohoku University (1972).
Clarifying the 1958 Cyanoacetate Geometry
In his 1958 paper, Antaki extended the chemistry to ethyl ethoxymethylenecyanoacetate. Later review literature can be easily misread in secondary indexing as suggesting that Antaki assigned a structure in error and was subsequently corrected. The primary sources do not support that interpretation.
Michael C. Seidel (1972) explicitly stated that “Antaki’s compound most probably was the isomeric 4-keto compound,” supporting rather than overturning Antaki's assignment. Similarly, Nishigaki (1971) confirmed Antaki's 4H-pyrido[1,2-a]pyrimidin-4-one ring assignments, refining only the cis/trans geometry of the open-chain intermediates using NMR—an instrument unavailable to Antaki in 1958. His core structural work stands fully intact.
Marketed Medicines on the Ring
The pyrido[1,2-a]pyrimidin-4-one core is a classic privileged scaffold—a molecular framework that, when decorated with different functional groups, yields potent activity against completely unrelated biological targets. Marketed therapies utilizing this ring span half a century of drug design:
| Medicine |
Clinical Use |
Form of the Ring |
| Risperidone |
Antipsychotic |
Reduced (tetrahydro) |
| Paliperidone (Invega) |
Antipsychotic (9-hydroxy metabolite) |
Reduced (tetrahydro) |
| Pemirolast |
Antiallergic (Ophthalmic conjunctivitis) |
Aromatic |
| Risdiplam (Evrysdi) |
First oral therapy for Spinal Muscular Atrophy |
Aromatic |
| Rimazolium (Probon) |
Non-narcotic analgesic (Marketed 1975) |
Reduced (tetrahydro) |
The ring system was structurally established by Antaki and Petrow in 1951. The reduction, the substitution, the drug design, and the pharmacology of each medicine are the work of the companies that developed them. What the medicines share is the core ring.
A Second Field: Agrochemicals
The same ring system later crossed over into crop protection. DuPont developed mesoionic derivatives of the pyrido[1,2-a]pyrimidinone framework into the commercial insecticides triflumezopyrim and dicloromezotiaz. In describing the class, the DuPont engineering team noted that these systems had been "known for several decades" before systematic biological screening began.
Historical Recognition
Antaki’s definitive work on this ring remains heavily cited throughout standard reference literature:
- The Canonical Review: Hermecz and Mészáros (Advances in Heterocyclic Chemistry, Vol. 33, 1983) names him directly in the running text as a primary structural figure and spectroscopic analyst.
- Comprehensive Heterocyclic Chemistry II (1996): Draws heavily on his 1951, 1958, and 1962 papers across its formal treatment of structure, synthesis, and spectroscopy.
- Encyclopedia of Reagents for Organic Synthesis (e-EROS): Lists his 1958 paper as the primary reference for the utility of the reagent ethyl ethoxymethyleneacetoacetate.
https://doi.org/10.1002/047084289X.re082
Primary Sources
- Antaki, H.; Petrow, V. J. Chem. Soc. 1951, 551–556.
- Antaki, H. J. Am. Chem. Soc. 1958, 80, 3066–3069.
- Antaki, H. J. Org. Chem. 1962, 27, 1371–1374.
- Antaki, H. Contributions to the Chemistry of Heterocyclic Compounds, Ph.D. thesis, University of London, 1950.
- Adams, R.; Pachter, I. J. Am. Chem. Soc. 1952, 74, 5491.
- Seidel, M. C. J. Org. Chem. 1972, 37, 600.
- Nishigaki, S.; Ichiba, M.; Shinomura, K.; Yoneda, F. J. Heterocyclic Chem. 1971, 8, 759.
www.hekmatantaki.org
#OrganicChemistry #MedicinalChemistry #DrugDiscovery #HistoryOfScience #Heterocyclic
